miR-27b inhibits fibroblast activation via targeting TGFβ signaling pathway

Xiangming Zeng1,2†, Chaoqun Huang2,3†, Lakmini Senavirathna2,3, Pengcheng Wang1* and Lin Liu2,3*

Abstract

Background: MicroRNAs are a group of small RNAs that regulate gene expression at the posttranscriptional level. They regulate almost every aspect of cellular processes. In this study, we investigated whether miR-27b regulates pulmonary fibroblast activation.

Results: We found that miR-27b was down-regulated in fibrotic lungs and fibroblasts from an experimental mouse model of pulmonary fibrosis. The overexpression of miR-27b with a lentiviral vector inhibited TGFβ1-stimulated mRNA expression of collagens (COL1A1, COL3A1, and COL4A1) and alpha-smooth muscle actin, and protein expression of Col3A1 and alpha-smooth muscle actin in LL29 human pulmonary fibroblasts. miR-27b also reduced contractile activity of LL29. TGFβ receptor 1 and SMAD2 were identified as the targets of miR-27b by 3'-untranslated region luciferase reporter and western blotting assays.

Conclusions: Our results suggest that miR-27b is an anti-fibrotic microRNA that inhibits fibroblast activation by targeting TGFβ receptor 1 and SMAD2. This discovery may provide new targets for therapeutic interventions of idiopathic pulmonary fibrosis.

Keywords: miR-27b, Fibroblast activation, TGFβ, Idiopathic pulmonary fibrosis

Background

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and usually fatal disease. The features of the disease are characterized by repeated injury and activation of alveolar epithelial cells, formation of myofibroblasts and excessive accumulation of extracellular matrix in the lung parenchyma [1]. The estimated prevalence of IPF in the United States is 14 to 27.9 per 100,000 people [2]. However, the etiology and molecular mechanisms of IPF initiation and progression are largely unclear.

Chronic lung inflammation had been considered preceding pulmonary fibrosis and played a major role in lung fibrogenesis. However, some evidence suggested that inflammation was not an important pathogenic event of IPF. For example, in the early or late course of IPF, including diseases similar to mild or moderate alveolitis, there was a lack of long-term effective response to anti-inflammation therapy [3]. Fibroblasts are the main source of abnormal extracellular matrix production in IPF. The TGFβ signaling is an important mediator of pulmonary fibrosis in both animals and humans. TGFβ modulates the activation of fibroblasts [1]. Alveolar epithelial cells also play an important role in the process of pathogenesis of IPF. The activated cells secrete soluble protein factors, including TGFβ, TNFα, endothelin-1 to exert their effects on fibroblasts [1].

MicroRNAs (miRNAs) are a group of endogenous non-coding small RNAs. More than 3000 mature miRNAs are found from plants to humans. miRNAs are the key regulators of many biological processes, and they function by inhibition of translation and degradation of target mRNAs to control protein expression in physiological and pathophysiological conditions [4]. miRNAs are involved in almost all aspects of cell physiology, including cell proliferation and differentiation, apoptosis, and diseases [5–8]. Based on computational analysis, the mRNA targets of miRNAs in most mammals are conserved due to selective pressure [9].

miR-27b has been reported to play a role in breast, liver, kidney or other organs. For example, antagonir of
miR-27b suppressed cell invasion in human breast cancer cell line, MDA-MB-231, whereas pre-miR-27b stimulated invasion in ZR75 breast cancer cells [10]. miR-27b synergized with anticancer drugs in a defined subgroup of liver and kidney cancer patients [11]. The overexpression or inhibition of miR-27b in HuH7 cells significantly decreased or increased the peroxisome proliferator-activated receptor (PPAR) alpha protein level [12]. miR-27b targets the 3'-untranslated region (3'-UTR) of PPARγ and inhibits its mRNA and protein expression in neuroblastoma cells [13].

Recently, miR-27b was identified as a major miRNA in modulating TGFβ-induced collagen I expression using a miRNA inhibitor library [14]. The inhibition of miR-27b increased COL1A1 expression. However, this study used lung epithelial cancer cell line A549 cells rather than pulmonary fibroblasts. During the course of this work, Cui et al. published a study showing that transfection of miR-27a-3p mimic into a fetal lung fibroblast cell line MRC-5 inhibited COL1A2 and alpha-smooth muscle actin (α-SMA) and this result was confirmed in IPF fibroblasts [15]. The use of a miRNA mimic could result in overwhelming expression of a miRNA since it by-pass the cellular regulatory system for the processing of a miRNA.

In this study, we investigated a role of miR-27b in fibroblast activation using a human lung fibroblasts and a lentiviral vector expressing a primary miR-27b, which is converted into a mature miRNA via the endogenous processing system after entering cells. We found that miR-27b inhibited fibroblast activation, and TGFβ receptor 1 (TGFBR1) and SMAD2 are direct targets of miR-27b. Our results suggest that miR-27b is an anti-fibrotic miRNA in pulmonary fibroblasts.

Methods

Bleomycin mouse fibrosis model and isolation of primary cells

The animal procedures were approved by the Institutional Animal Care and Use Committee at the Oklahoma State University (VM-15–38). Bleomycin or saline was delivered to the lungs of C57BL/6 male mice (6–8 weeks) via nasal instillation at a dose of 3 U/kg body weight. On day 14 mice were sacrificed, and lung tissues were collected. Fibroblasts and alveolar epithelial type II cells (AEC II) were isolated from the lungs of saline or bleomycin-treated mice according to the previously described protocols [16, 17]. Alveolar epithelial type I cells (AEC I) were obtained by culturing AEC II in Dulbecco’s Modified Eagle Medium (DMEM) for 5 days [18].

RNA isolation

Total RNAs were isolated from lung tissues or cells by using Tri Reagents (Molecular Research Center, Cincinnati, OH). The RNA concentration and quality were determined by NanoDrop ND-1000 Spectrophotometer.

Construction of vectors

The primary hsa-miR-27b was PCR-amplified from human genomic DNA (Promega, Madison, WI) with the following primers: forward, TTTCCTGAAGGATTCCACGCAACCAC and reverse, TTTGAATTCGGCTAGCATTCCCAGCAGGAGA. The PCR product was inserted into a modified lentiviral vector pLVX (Clontech, Mountain View, CA) the downstream of its green fluorescent protein (GFP) at Xhol and EcoRI as described [19].

The 3'-UTRs of human TGFβ receptor 1 (TGFBR1) and SMAD2 were PCR-amplified from human genomic DNA with the following primers: TGFBR1 forward, GCTAGCTGAATATTCTCACAATCAAGCTTT and reverse, GTCGACGTGAGAAATCATGTATTACAACT. SMAD2 forward, GCTAGCTTTTCTCTAGTGTATGTAAGGAACG and reverse, GTCGACACAGATGTAGCACACAAATAT. TGFBR1-UTR or SMAD2-UTR was inserted into the pmirGlo vector (Promega) the downstream of firefly luciferase gene at Nhe I and Sac I. All of the constructs were confirmed by DNA sequencing.

Preparation of lentivirus

To produce lentivirus overexpressing miR-27b, lentimmiR-27b or its control plasmid was transfected to HEK 293 T cells along with Lenti-X HTX Packaging mix (Clontech) by using Lipofectamine 2000. After a 48-h transfection, the media containing viruses were collected. For virus titer determination, HEK 293 T cells were split into a 12-well plate at a density of 5 x 10^5 cells per well. Cells were infected with lentivirus at a series of dilutions. 48 h post infection, virus titer was determined by counting GFP-positive cells (10 fields per well) under a fluorescence microscope.

Infection of fibroblasts with a lentiviral miR-27b

LL29 lung fibroblasts were purchased from American Type Culture Collection (ATCC, Manassa, VA, CCL-134) and were maintained in F12K medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S). The fibroblasts were seeded on 6-well plates at a density of 2–5 x 10^5/well. After 24 h, cells were infected with a lentiviral miR-27b or its control at a multiplicity of infection (MOI) of 50. 48 h post infection, cells were stimulated with TGFβ (5 ng/ml). After another 48 or 72 h, cells were collected for RNA and protein analyses.

Real-time PCR

Total RNA was reverse-transcribed into cDNA using Moloney Murine Leukemia Virus reverse transcriptase.
For miRNA quantitation, total RNA was poly (A)-tailed using an A-Plus Poly (A) Polymerase Tailing Kit (Episcience, Madison, WI) before reverse transcription. The following primers were used: COL1A1, Forward: CGAGACAAGAGAGGAC; reverse: GCCGTAGTCCTCCTCT; COL3A1, Forward: CTCTGGGCAATGTTG; reverse: GCTCAGGTCCCACATTG; COL4A1, forward: CGTGGCAGGATGACCTT; reverse: CTGCATTTCTGTCAGCAT; α-SMA, forward: GTGTTGCCCCTGGAAGAGCAT; and reverse: CAGGCTGGATAAGCACCATAAT; microRNA-universe reverse primer: GCAGACAGAGTTATAGGCAG; RNU6 forward primer: AGAGAACATTAGCATGGCCCCTT; miR-27b forward primer: TTGACTGGCTTATAGGTTG; and reverse: CCTCAGTGGCTAAGTTCTG. Real-time PCR was performed using SYBR Green master mix on an ABI 7500 fast system (Applied Biosystems, Foster City, CA). The thermal temperature were: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s, 60°C for 30 s, and 65°C for 30 s. The endogenous reference genes were glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or RNU6. The comparative ΔCt method was used to calculate the relative mRNA and miRNA expression levels.

Luciferase reporter assay
miR-27b or its control plasmid (150 ng) were cotransfected into HEK 293 T cells using Lipofectamine 2000 with TGFBR1-UTR or SMAD2-UTR plasmid (5 ng), which contains a Renilla luciferase gene for normalization. After a 48 h transfection, the cells were harvested, and luciferase activities were measured using the Dual Luciferase Reporter Assay System (Promega).

Western blot
Proteins (10–20 μg) were separated on SDS-PAGE and transferred onto nitrocellulose membranes. After being incubated with primary antibodies, the membranes were washed with Tris-buffered saline (pH 7.5) and Tween 20 and incubated with horseradish peroxidase-conjugated anti-mouse or rabbit secondary antibodies for 1 h. The target proteins were visualized with Super Signal West Pico Chemiluminescents Substrate and analyzed with Amersham 600 Molecular Imager. The following antibodies and dilutions were used: mouse anti-α-SMA monoclonal antibody (1:1000; Sigma), rabbit anti-β-actin monoclonal antibody (1:1000; Santa Cruz), rabbit anti-TGFBR1 polyclonal antibody (1:500; Santa Cruz), rabbit anti-SMAD2 polyclonal antibody (1:500; Santa Cruz), rabbit anti-Col3A1 polyclonal antibody (1:500; Santa Cruz), goat anti-rabbit monoclonal second antibody (1:2000; Sigma), and goat anti-mouse monoclonal second antibody (1:2000; Sigma).

Fibroblast contraction assay
LL29 fibroblasts were seeded in 6-well plates at a density of 1–2×10^5 cells per well overnight and infected with miR-27b or its control lentivirus at a MOI of 50 for 48 h. The cells were treated with TGFβ1 (5 ng/ml) for another 48 h. The cells were trypsinized and mixed with rat tail collagen I (BD Bioscience, Cat# 354236) to a final concentration of 1×10^5 cells/ml and 1 mg/ml of collagen 1, followed by the addition of 15 μl 0.5 M NaOH to 1 ml of the cells. The cells were then added to 24-well BSA-coated plates (500 μl/well). After a 30-min incubation, medium with or without TGFβ (5 ng/ml) were added (500 μl/well). Cells were incubated for 48 h and images were taken. The gel areas were quantified using Image J software.

Statistics
All experiments were performed with at least three independent replicates. For statistical analysis, student t-test was used for two group comparisons and ANOVA, followed by Turkey’s test for multiple group comparisons. P < 0.05 was considered significance.

Results
miR-27b is down-regulated in the lungs and fibroblasts from bleomycin-treated mice
We determined miR-27b expression levels in the fibrotic lungs induced by bleomycin in mice by real-time PCR. The expression of miR-27b in the lung tissue of bleomycin-treated mice was decreased significantly compared to that of the control mice (Fig. 1). To examine which types of the lung cells account for the decrease, we isolated fibroblasts and alveolar epithelial cells from the bleomycin-treat mice. The expression level of miR-27b in fibroblasts was much higher than alveolar epithelial type I and type II cells (AEC I and AEC II). Bleomycin treatment reduced miR-27b expression in the fibroblasts (Fig. 1), suggesting that fibroblasts are the cells responsible for the reduction of miR-27b in the fibrotic lungs.

miR-27b inhibits pulmonary fibroblast activation
To study whether miR-27b affects fibroblasts’ function, we overexpressed miR-27b in LL29 human pulmonary fibroblasts using a lentiviral vector and determined the effect of miR-27b on TGFβ1-mediated collagen and α-SMA expression by real-time PCR and western blotting. The overexpression of miR-27b in LL29 fibroblasts were confirmed (Fig. 2a). The mRNA expression of COL1A1, COL3A1, COL4A1 and α-SMA was increased by TGFβ1 treatment, and this increase was suppressed by miR-27b overexpression (Fig. 2b). Moreover, the TGFβ1-induced protein expression of Col3A1 and α-SMA was also inhibited by miR-27b overexpression (Fig. 2c, d). These results indicate that miR-27b represses fibroblast activation.
miR-27b attenuates the contractile activity in pulmonary fibroblasts
The contraction process is known to be mediated by specialized fibroblasts in IPF and TGFβ signaling pathway regulates this process. Therefore, we investigated whether miR-27b influences the contractility of pulmonary fibroblasts. As shown in Fig. 3, miR-27b inhibited the TGFβ1-induced contractility of LL29 fibroblasts.

miR-27b directly targets TGFBR1 and SMAD2
Because miR-27b inhibits TGFβ1-induced fibroblast activation, it likely targets the components in the TGFβ pathway.
signaling pathway. Using TargetScan, TGFBR1 and SMAD2 were identified as the potential targets of miR-27b (Fig. 4a). Next we constructed 3'-UTR luciferase reporter vectors and performed the dual luciferase assay to validate whether TGFBR1 and SMAD2 are the direct targets of miR-27b. As shown in Fig. 4b, miR-27b significantly inhibited the luciferase activities of TGFBR1-UTR and SMAD2-UTR reporters. Furthermore, TGFBR1 and SMAD2 protein expression was inhibited by miR-27b in LL29 fibroblasts (Fig. 4c, d).

Discussion

miRNAs play important roles in various biological processes, such as cell proliferation, differentiation, apoptosis, and other functions. miRNAs show different expression profiles in many diseases including IPF. Abnormal expression of miRNAs may contribute to the development of many diseases. miRNAs may be potentially utilized in the treatment of human diseases, such as infectious and metabolic diseases [20, 21]. In the present study, we demonstrated that miR-27b was down-regulated in fibrotic lungs and fibroblasts from bleomycin-induced mouse pulmonary fibrosis model. In contrast, miR-27a-3p was found to be increased in the fibroblasts isolated from the lungs of the bleomycin-treated mice although the same authors found that miR-27a-3p was decreased in IPF fibroblasts compared to normal lung fibroblasts [15]. Additionally, TGFβ inhibited miR-27b expression in lung epithelial A549 cells [14], but increased miR-27a expression in MRC-5 fibroblasts [15]. The reasons for these differences remain to
be determined, but could be due to the differences in transcription because miR-27a-3p and miR-27b are located in different chromosomes, chromosome 19 and chromosome 9, respectively. However, there is only one base difference between miR-27a-3p and miR-27b.

The abnormal activation of fibroblasts is one of the major factors driving fibrotic progression in IPF [22–24]. TGFβ activates fibroblasts and enhances collagen synthesis and extracellular matrix deposition [25–27]. In the current study, we found that ectopic overexpression of miR-27b suppressed TGFβ-induced fibroblast activation, as evidenced by the decreased collagen synthesis, inhibition of α-SMA mRNA and protein expression, and enhanced contractile ability. A recent report shows that miR-27b inhibitor increased TGFβ-induced COL1A1 expression in lung epithelial A549 cells [14]. The significance of this regulation in lung epithelial cells is unclear since pulmonary fibroblasts are the major cells for extracellular matrix deposition in IPF. Most recently, miR-27a-3p has been shown to inhibit TGFβ-induced COL1A2 and α-SMA expression and gel contractility in MRC-5 fibroblasts [15]. However, a miR-27b-3p mimic was used for these studies, which may result in overwhelmed expression of miR-27a. Further, MRC-5 fibroblasts are derived from fetal lungs, which may not be the best fibroblast cell line for studying IPF, which normally occurs in patients between the ages of 50 and 70 years. Whether miR-27a-3p and miR-27b have the same functions or are redundant in pulmonary fibroblasts needs further investigations.

Several miRNAs are involved in the regulation of pulmonary fibrosis through the TGFβ/SMAD pathway, including miR-21, miR-26a and miR-29 [28–30]. We suspected that miR-27b may act in a similar mechanism in pulmonary fibrosis. Indeed, TGFBR1 and SMAD2 were identified as potential targets of miR-27b by TargetScan. The dual-luciferase reporter assay confirmed that miR-27b functioned through a direct binding to its 3′-UTR of TGFBR1 and SMAD2. The endogenous protein expressions of these targets were reduced in LL29 fibroblasts by miR-27b, which further confirmed that TGFBR1 and SMAD2 are the targets of miR-27b. Using similar approaches, Cui et al. found that miR-27a-3p targeted SMAD2/4 in fetal lung MRC-5 fibroblasts [15]. However, a miR-27b-3p mimic was used for these studies, which may result in overwhelmed expression of miR-27a. Further, MRC-5 fibroblasts are derived from fetal lungs, which may not be the best fibroblast cell line for studying IPF, which normally occurs in patients between the ages of 50 and 70 years. Whether miR-27a-3p and miR-27b have the same functions or are redundant in pulmonary fibroblasts needs further investigations.

To sum up, our present studies show that miR-27b plays an important role in the pulmonary fibroblast activation by regulating TGFBR1 and SMAD2.

Conclusions

Acknowledgements

None.

Funding

This work was supported by the National Heart, Lung and Blood Institute under Award Number R01 HL116876, the National Institute of General Medical Sciences under Award number P20GM103648 and the Oklahoma Center for Adult Stem Cell Research (to LL) and Guangdong Natural Science Foundation (2014A030313370), and Jinan University Innovation Foundation (21615420) (to PW).

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Authors’ contributions

XZ, CH, LS carried out experiments. XZ, CH analyzed data. XZ, CH, PW, LL designed and wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not Applicable.

Acknowledgements

The authors declare that they have no competing interests.

Funding

This work was supported by the National Heart, Lung and Blood Institute under Award Number R01 HL116876, the National Institute of General Medical Sciences under Award number P20GM103648 and the Oklahoma Center for Adult Stem Cell Research (to LL) and Guangdong Natural Science Foundation (2014A030313370), and Jinan University Innovation Foundation (21615420) (to PW).

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Authors’ contributions

XZ, CH, LS carried out experiments. XZ, CH analyzed data. XZ, CH, PW, LL designed and wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

None.

Funding

This work was supported by the National Heart, Lung and Blood Institute under Award Number R01 HL116876, the National Institute of General Medical Sciences under Award number P20GM103648 and the Oklahoma Center for Adult Stem Cell Research (to LL) and Guangdong Natural Science Foundation (2014A030313370), and Jinan University Innovation Foundation (21615420) (to PW).

Received: 10 May 2016 Accepted: 21 December 2016

Published online: 17 January 2017

References

1. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J exp med. 2011;208:1339–50.
2. Nalysnyk L, Cid-Ruzafa J, Rotella P, Eiser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur respir rev. 2012;21:355–61.
3. Rafi R, Juarez MM, Albertson TE, Chan AL. A review of current and novel therapies for idiopathic pulmonary fibrosis. J thorac dis. 2013;5:48–73.
4. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat rev mol cell biol. 2010;11:252–63.
5. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.
6. Gafro G, Calin GA, Croce CM. MicroRNAs in cancer. Annu rev med. 2009;60:167–79.
7. Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat rev mol cell biol. 2009;10:116–25.
8. Wang Y, Stricker HM, Guo D, Liu L. MicroRNA: past and present. Front bioi. 2007;12:2316–29.
9. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of miRNAs. Genome res. 2009;19:92–105.
10. Wang Y, Rathinam R, Walsh A, Alkhari SK. ST14 (suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation. J biol chem. 2009;284:23094–106.
11. Mu W, Hu C, Zhang H, Qu Z, Cen J, Qiu Z, Li C, Ren H, Li Y, He X, Shi X, Hui L. miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell res. 2015;25:477–95.
12. Kida X, Nakajima M, Mohri T, Oda Y, Takagi S, Fukami T, Yoko T. PPApAlpha is regulated by miR-21 and miR-27b in human liver. Pharm res. 2011;28:2467–76.
13. Lee JJ, Drakali A, Iliopoulos D, Struhl K. MiR-27b targets PPARGamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene. 2012;31:3818–25.
14. Graham JR, Williams CMM, Yang ZY. MicroRNA-27b targets gremlin 1 to modulate fibrotic responses in pulmonary cells. J cell biochem. 2014;115:1539–48.
15. Cui H, Banerjee S, Xie N, Ge J, Liu RM, Matalon S, Thannickal VJ, Liu G. MicroRNA-27a-3p is a negative regulator of lung fibrosis by targeting myofibroblast differentiation. Am j respir cell mol biol. 2016;54:843–52.
16. Guo Y, Mishra A, Howland E, Zhao C, Shukla D, Weng T, Liu E. Platelet-derived Wnt antagonist dickkopf-1 is implicated in ICAM-1/VCAM-1-mediated neutrophilic acute lung inflammation. Blood. 2015;126:2220–9.
17. Bruce MC, Honaker CE, Cross RJ. Lung fibroblasts undergo apoptosis following alveolarization. Am j respir cell mol biol. 1999;20:228–36.
18. Bhaskaran M, Kolliputi N, Wang Y, Gou D, Chintagari NR, Liu L. Transdifferentiation of alveolar epithelial type II cells to type I cells involves autocrine signaling by transforming growth factor beta 1 through the Smad pathway. J biol chem. 2007;282:3968–76.
19. Zhao C, Huang C, Weng T, Xiao M, Ma H, Liu L. Computational prediction of MicroRNAs targeting GABA receptors and experimental verification of miR-181, miR-216 and miR-203 targets in GABA-A receptor. BMC res notes. 2012;5:91.
20. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Crit pract pharmacol. 2013;19:98–104.
21. Hydbring P, Badalain-Very G. Clinical applications of microRNAs. F1000Res. 2013;2:136.
22. Lim MJ, Ahn J, Yi JY, Kim MH, Son AR, Lee SL, Lim D5, Kim SS, Kang MA, Han Y, Song JY. Induction of galectin-1 by TGF-beta1 accelerates fibrosis through enhancing nuclear retention of Smad2. Exp cell res. 2014;326:125–35.
23. Kottmann RM, Kulkarni AA, Smolnycki KA, Lyda E, Dahayanayke T, Salibi R, Honnons S, Jones C, Isen NG, Hu JZ, Nathan SD, Grant G, Phripps RP, Sime PJ. Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-beta. Am j respir crit care med. 2012;186:740–51.
24. Lepparanta O, Sens C, Salmenkivi K, Kinnula VL, Keski-Oja J, Myllarniemi M, Koli K. Regulation of TGF-beta storage and activation in the human idiopathic pulmonary fibrosis lung. Cell tissue res. 2012;348:491–503.
25. Chen J, Xia Y, Lin X, Feng XH, Wang Y. Smad3 signaling activates bone marrow-derived fibroblasts in renal fibrosis. Lab invest. 2014;94:545–56.
26. Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts. Curr med chem. 2006;13:1877–93.
27. Judge JL, Owens KM, Pollock SJ, Woeller CF, Thatcher TH, Williams JP, Phripps RP, Sime PJ, Kottmann RM. Ionizing radiation induces myofibroblast differentiation via lactate dehydrogenase. Am j physiol lung cell mol physiol. 2015;309:L879–87.
28. Gao Y, Lu J, Zhang Y, Chen Y, Gu Z, Jiang X. Baicalein attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of miR-21. Pulm pharmacol ther. 2013;26:649–54.
29. Li X, Xu C, Pan Z, Zhang Y, Xu Z, Chen Y, Li T, Li X, Liu Y, Huangfu L, Lu Y, Zhang Z, Yang B, Gita S, Lu Y, Shan H, Du Z. The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis. Mol ther. 2014;22:1122–33.
30. Xiao J, Meng XM, Huang XR, Chung AC, Feng YL, Hui DS, Yu CM, Sung JJ, Lan HY. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol ther. 2012;20:1251–60.